[1] de Pauw B,Walsh T J,Donnelly J P,et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the National Institute of allergy and infectious diseases mycoses study group(EORTC/MSG) C[J]. Clin Infect Dis,2008,46(12):1813
[2] Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition[S]. ClSI document M27-A2. Wayne,Pennsylvania: CLSI,2002
[3] Clinical and Laboratory Standards Institute.Reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement[S]. ClSI document M27-S4. Wayne,Pennsylvania: CLSI,2012
[4] Cortegiani A,Giovanni M,Chowdhary A. What's new on emerging resistant Candida species[J]. Intensive Care Med,2018,45(4):512
[5] Bassetti M,Garnacho-Montero J,Calandra T A,et al.Intensive care medicine research agenda on invasive fungal infection in critically ill patients[J]. Intensive Care Med,2017,43(9):1225
[6] Maubon D,Garnaud C,Calandra T,et al. Resistance of candida spp. to antifungal drugs in the ICU: where are we now[J]. Intensive Care Med,2014,40(9):1241
[7] Chen M,Xu Y,Hong N,et al. Epidemiology of fungal infections in China[J]. Front Med,2018,12(1,SI):58
[8] Xiao M,Sun Z Y,Kang M,et al. Five-Year national surveillance of invasive candidiasis: species distribution and azole susceptibility from the China hospital invasive fungal surveillance net(CHIF-NET) study[J]. J Clin Microbiol,2018,56(7):e00518.
[9] Barchiesi F,Orsetti E,Osimani P,et al. Factors related to outcome of bloodstream infections due to Candida parapsilosis complex[Z].2016:387
[10] 陈丽燕,邱秀媚,牛玉娟,等. 危重患者导管相关性血流感染危险评估的应用研究[J]. 中华医院感染学杂志,2015,25(4):845
[11] 叶晓燕,金彩香,韩智云. 中心静脉导管相关性血流感染的危险因素与预防研究[J]. 中华医院感染学杂志,2015,25(9):2157
[12] Li W,Hu Y A,Li F Q,et al. Distribution of yeast isolates from invasive infections and their in vitro susceptibility to antifungal agents: evidence from 299 cases in a 3-Year (2010 to 2012) surveillance study[J]. Mycopathologia,2015,179(5/6):397
[13] Castanheira M,Messer S A,Rhomberg P R,et al. 2016. Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY antifungal surveillance program[J]. Diagn Microbiol Infect Dis,2013,85(2):200
[14] Kauffman P A,David R A. Clinical practice guideline for the management of candidiasis:2016 update by the Infectious Diseases Society of Americal[J]. Clin Infect Dis,2016,62(4):409
[15] Perfect J R,Dismukes W E,Dromer F A,et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America[J]. Clin Infect Dis,2010,50(3):291
[16] Bal A M,Mcgill M. Rapid species identification of Candida directly from blood culture broths by Sepsityper-MALDI-TOF mass spectrometry: impact on antifungal therapy[J]. J R Coll Physicians Edinb,2018,48(2):114
[17] Elisabeth Presterl. Clinically relevant mycoses[DB/OL]. Springer International Publishing,2019
[1]陈倩倩,宋缘缘,唐洪影,等.2015-2018年血流感染病原菌菌群分布及耐药性分析[J].天津医科大学学报,2020,26(03):271.
CHEN Qian-qian,SONG Yuan-yuan,TANG Hong-ying,et al.Distribution and analysis of antimicrobial resistance of pathogens caused bloodstream infection from 2015 to 2018[J].Journal of Tianjin Medical University,2020,26(01):271.